Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737995 | 0.89 | P2RX7 (0.48) | NPC1RAB9AP2RX7LMNAKMT2A | |
| SCHEMBL13737202 | 0.75 | NPC1 (0.53) | NPC1RAB9ALMNAMAPTCASP3 | |
| SCHEMBL15514985 | 0.73 | KMT2A (0.45) | LMNAKMT2AMAPTCA1CA2 | |
| SCHEMBL11380594 | 0.71 | CA1 (0.63) | NPC1RAB9AP2RX7LMNAKMT2A | |
| SCHEMBL15233020 | 0.71 | ROCK2 (0.46) | NPC1RAB9AP2RX7LMNAMAPT | |
| SCHEMBL15514972 | 0.71 | NPC1 (0.41) | NPC1RAB9ALMNACASP3 | |
| SCHEMBL13738422 | 0.71 | NPC1 (0.41) | NPC1RAB9ALMNACASP3 | |
| SCHEMBL10489837 | 0.70 | NPC1 (0.76) | NPC1RAB9AMAPTCASP3 | |
| SCHEMBL31455313 | 0.69 | NPC1 (0.59) | NPC1RAB9ACASP3 | |
| SCHEMBL20326798 | 0.69 | NPC1 (0.52) | NPC1RAB9AP2RX7LMNACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561230-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9187494-B2 | Aryl-substituted tricyclic sulfonamides as methionyl aminopeptidase 2 modulators | ZAFGEN, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2705036-B1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | ZAFGEN, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2705036-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012154678-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073623-A1 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same | DNPEP, METAP2, ANPEP | NPC1 2178/4885RAB9A 4404/4885P2RX7 1761/4885 |
| US-20160256469-A1 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, METAP2, ANPEP | NPC1 2178/4885RAB9A 4404/4885P2RX7 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.